BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti‐PD‐1/PD‐L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity
Abstract To improve response rate of monotherapy of immune checkpoint blockade (ICB), it is necessary to find an emerging target in combination therapy. Through analyzing tumor microenvironment (TME)‐related indicators, it is validated that BCAT2 shapes a noninflamed TME in bladder cancer. The outco...
Main Authors: | Zhiyong Cai, Jinbo Chen, Zhengzheng Yu, Huihuang Li, Zhi Liu, Dingshan Deng, Jinhui Liu, Chunliang Chen, Chunyu Zhang, Zhenyu Ou, Minfeng Chen, Jiao Hu, Xiongbing Zu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-03-01
|
Series: | Advanced Science |
Subjects: | |
Online Access: | https://doi.org/10.1002/advs.202207155 |
Similar Items
-
S100A5 Attenuates Efficiency of Anti‐PD‐L1/PD‐1 Immunotherapy by Inhibiting CD8+ T Cell‐Mediated Anti‐Cancer Immunity in Bladder Carcinoma
by: Huihuang Li, et al.
Published: (2023-09-01) -
A novel signature to predict the neoadjuvant chemotherapy response of bladder carcinoma: Results from a territory multicenter real-world study
by: Huihuang Li, et al.
Published: (2022-11-01) -
Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
by: Masatoshi Kudo
Published: (2022-05-01) -
Senescence-specific molecular subtypes stratify the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer
by: Luzhe Yan, et al.
Published: (2025-02-01) -
An EMT-based risk score thoroughly predicts the clinical prognosis, tumor immune microenvironment and molecular subtypes of bladder cancer
by: Zicheng Xiao, et al.
Published: (2022-09-01)